Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Gains from Sales and Divestitures (2020 - 2024)

Historic Gains from Sales and Divestitures for Relay Therapeutics (RLAY) over the last 5 years, with Q4 2024 value amounting to $2.1 million.

  • Relay Therapeutics' Gains from Sales and Divestitures rose 14051.62% to $2.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.1 million, marking a year-over-year increase of 14051.62%. This contributed to the annual value of $2.1 million for FY2024, which is 14051.62% up from last year.
  • Relay Therapeutics' Gains from Sales and Divestitures amounted to $2.1 million in Q4 2024, which was up 14051.62% from $883652.0 recorded in Q4 2023.
  • Relay Therapeutics' 5-year Gains from Sales and Divestitures high stood at $2.1 million for Q4 2024, and its period low was $84489.0 during Q4 2021.
  • Over the past 5 years, Relay Therapeutics' median Gains from Sales and Divestitures value was $579825.0 (recorded in 2020), while the average stood at $814324.4.
  • As far as peak fluctuations go, Relay Therapeutics' Gains from Sales and Divestitures plummeted by 8542.85% in 2021, and later soared by 37145.78% in 2022.
  • Over the past 5 years, Relay Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $579825.0 in 2020, then plummeted by 85.43% to $84489.0 in 2021, then soared by 371.46% to $398330.0 in 2022, then skyrocketed by 121.84% to $883652.0 in 2023, then skyrocketed by 140.52% to $2.1 million in 2024.
  • Its Gains from Sales and Divestitures stands at $2.1 million for Q4 2024, versus $883652.0 for Q4 2023 and $398330.0 for Q4 2022.